Current filters:


Popular Filters

1940 to 1964 of 2554 results

BioAlliance says partner Vestiq debuts Oravig in USA


French biotech firm BioAlliance Pharma (Euronext Paris - BIO) has announces the launch of Oravig (miconazole…

BioAlliance PharmaBiotechnologyLoramycMarkets & MarketingNorth AmericaOncologyOravigPharmaceuticalVestiq Pharmaceuticals

Lonza to invest in new antibody drug conjugate manufacturing capacity to meet growing demand


Swiss pharmaceutical ingredients and specialty chemicals firm Lonza (SIX: LONN) plans to invest 14 million…


FDA approves SOBI's Kineret for the treatment of NOMID


Biotech firm Swedish Orphan Biovitrum (STO: SOBI) today announced that the US Food and Drug Administration…

AmgenBiotechnologyInflammatory diseasesKineretNorth AmericaRegulationSobiSwedish Orphan Biovitrum

arGEN-X expands antibody deal with Shire; initiates ARGX-110 trial in cancer


Netherlands and Belgium-based preclinical stage biotech firm arGEN-X, specialized in the discovery and…

arGEN-XARGX-110BiotechnologyLicensingOncologyRare diseasesResearchShire

Gilead Sciences updates on hepatitis C development programs


US biotech firm Gilead Sciences (Nasdaq: GILD) presented several updates regarding its late-stage pipeline…

Anti-viralsBiotechnologyGilead SciencesGS-5885Researchsofosbuvir

Big pharma will increasingly tap M&A to close $100 billion growth gap


Big pharma companies are facing a widening "growth gap" that will increase pressure to drive growth through…

BiotechnologyFinancialMergers & AcquisitionsPharmaceutical

Ethris enters SNIM modified RNA alliance with Shire


German biotech firm Ethris GmbH has initiated a research based alliance focused on the development and…

BiotechnologyEthris GmbHGeneticsLicensingPharmaceuticalResearchShire

Pharmaceutical M&A deals in 2012


Details for the 131 M&A announcements in 2012 recorded by The Pharma Letter are provided in the full…

BiotechGenericsMergers & AcquisitionsPharmaceutical

Biogen Idec files for US approval of hemophilia B treatment


US biotech firm Biogen Idec (Nasdaq: BIIB) on Friday announced it has submitted a Biologics License Application…

Biogen IdecBiotechnologyNorth AmericaRegulationrFIXFcrFVIIIFcSwedish Orphan Biovitrum

Eight US FDA approvals in December boost 2012 to banner year for new drugs


The US Food and Drug Administration approved eight new drugs in December pushing the year's total to…

BiotechnologyFinancialNorth AmericaPharmaceuticalRegulation

Biogen Idec to drop ALS drug after failure in Ph III trial


Shares of US biotech firm Biogen Idec (Nasdaq: BIIB) fell as much as 8% to $138.05 in pre-market trading…

Biogen IdecBiotechnologydexpramipexoleNeurologicalResearch

Repligen in $70 million deal with Pfizer for SMA program


USA-based Repligen (Nasdaq: RGEN) saw its share jump 5.6% to $6.63, after the company revealed it has…

BiotechnologyLicensingNeurologicalPfizerPharmaceuticalRare diseasesRepligenRG3039

Questcor Pharmaceuticals to acquire BioVectra for around $50 million


California, USA-based Questcor Pharmaceuticals (Nasdaq: QCOR) has signed a definitive agreement to acquire…

BiotechnologyBioVectraGenericsMergers & AcquisitionsPharmaceuticalProductionQuestor Pharmaceuticals

US FDA approves Merck KGaA's Rebif Rebidose


German drug major Merck KGaA's (MRK: DE) US subsidiary EMD Serono and pharma behemoth Pfizer (NYSE: PFE)…

BiotechnologyEMD SeronoMerck KGaANeurologicalNorth AmericaPfizerPharmaceuticalRebifRegulation

Monoclonal antibodies market dominated by Remicade and Avastin


With the rollout of at least eight new therapeutic monoclonal antibody products and expanded indications…

Anti-Arthritics/RheumaticsBiotechnologyMarkets & MarketingOncology

Emergent BioSolutions gets exclusive US commercial rights to pandemic flu vaccine candidate


US vaccine maker Emergent BioSolutions (NYSE: EBS) has signed a license agreement with fellow USA-based…

BiotechnologyEmergent BioSolutionsLicensingNorth AmericaVaccinesVaxInnate Corp

1940 to 1964 of 2554 results

Back to top